Evidence mapPaperPMID 38495306Full record

ReviewBrain communications2024

Neurovascular coupling impairment as a mechanism for cognitive deficits in COVID-19.

Cameron D Owens, Camila Bonin Pinto, Sam Detwiler, Lauren Olay, Ana Clara da C Pinaffi-Langley, Peter Mukli, Anna Peterfi, Zsofia Szarvas, Judith A James, Veronica Galvan and 6 more

Open access · goldAbstract readReview
In one paragraph

Review in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Neuroimmune pathophysiology of long COVID.Psychiatry and clinical neurosciences · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Cameron D OwensOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.ORCID https://orcid.org/0000-0002-5020-2810
Camila Bonin PintoOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Sam DetwilerOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Lauren OlayOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Ana Clara da C Pinaffi-LangleyOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Peter MukliOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Anna PeterfiOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Zsofia SzarvasOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Judith A JamesOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Veronica GalvanOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Stefano TarantiniOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Anna CsiszarOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Zoltan UngvariOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Angelia C KirkpatrickVeterans Affairs Medical Center, Oklahoma City, OK 73104, USA.
Calin I ProdanVeterans Affairs Medical Center, Oklahoma City, OK 73104, USA.
Andriy YabluchanskiyOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.ORCID https://orcid.org/0000-0002-9648-7161
Semmelweis University · HUUniversity of Oklahoma Health Sciences Center · USVeterans Health Administration · USOklahoma Medical Research Foundation · US

Funding

Tissue Pathology and Biospecimen Shared ResourceP30CA225520 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2025 to 2025
$2.2M
Research Development CoreP30AG050911 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2025 to 2025
$1.3M
Radiation-induced astrocyte dysfunction and cognitive declineR01NS100782 · NINDS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZOLTAN Istvan UNGVARI · 2021 to 2022
$686k
Effects of NAD restoration on neurovascular coupling in community dwelling older adultsR01AG075834 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2025 to 2025
$643k
Cerebral microhemorrhages and gait abnormalities in agingR01AG055395 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2025 to 2025
$424k
GEROSCIENCE TRAINING PROGRAM IN OKLAHOMAT32AG052363 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2025 to 2025
$373k
Midlife Obesity, Neurovascular Senescence and Cognitive DeclineK01AG073614 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2025 to 2025
$120k
BLRD Research Career Scientist Award ApplicationIK6BX006026 · OKLAHOMA CITY VA MEDICAL CENTER · 2025 to 2025
Procoagulant platelets as biomarkers for post-COVID-19 cognitive declineI01CX002578 · OKLAHOMA CITY VA MEDICAL CENTER · 2025 to 2025
Pathogenic soluble aggregated tau as a driver of brain vascular dysfunction in Alzheimer's diseaseI01BX002211 · OKLAHOMA CITY VA MEDICAL CENTER · 2025 to 2025
BLRD VA I01 BX002211BLRD VA IK6 BX006026CSRD VA I01 CX000340CSRD VA I01 CX002578NCI NIH HHS P30 CA225520NIA NIH HHS K01 AG073614NIA NIH HHS R01 AG055395NIA NIH HHS R01 AG075834NIA NIH HHS T32 AG052363NINDS NIH HHS R01 NS100782
6 · The paper itself

Abstract

Components that comprise our brain parenchymal and cerebrovascular structures provide a homeostatic environment for proper neuronal function to ensure normal cognition. Cerebral insults (e.g. ischaemia, microbleeds and infection) alter cellular structures and physiologic processes within the neurovascular unit and contribute to cognitive dysfunction. COVID-19 has posed significant complications during acute and convalescent stages in multiple organ systems, including the brain. Cognitive impairment is a prevalent complication in COVID-19 patients, irrespective of severity of acute SARS-CoV-2 infection. Moreover, overwhelming evidence from in vitro, preclinical and clinical studies has reported SARS-CoV-2-induced pathologies in components of the neurovascular unit that are associated with cognitive impairment. Neurovascular unit disruption alters the neurovascular coupling response, a critical mechanism that regulates cerebromicrovascular blood flow to meet the energetic demands of locally active neurons. Normal cognitive processing is achieved through the neurovascular coupling response and involves the coordinated action of brain parenchymal cells (i.e. neurons and glia) and cerebrovascular cell types (i.e. endothelia, smooth muscle cells and pericytes). However, current work on COVID-19-induced cognitive impairment has yet to investigate disruption of neurovascular coupling as a causal factor. Hence, in this review, we aim to describe SARS-CoV-2's effects on the neurovascular unit and how they can impact neurovascular coupling and contribute to cognitive decline in acute and convalescent stages of the disease. Additionally, we explore potential therapeutic interventions to mitigate COVID-19-induced cognitive impairment. Given the great impact of cognitive impairment associated with COVID-19 on both individuals and public health, the necessity for a coordinated effort from fundamental scientific research to clinical application becomes imperative. This integrated endeavour is crucial for mitigating the cognitive deficits induced by COVID-19 and its subsequent burden in this especially vulnerable population.

Indexed as

cognitive impairmentendotheliumneurovascular uncouplingoxidative stressSARS-CoV-2

Identifiers

PMID38495306
PMCPMC10943572
OpenAlexW4392563817

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.